Stockscreener 앱 받기
4.13
0.24%
-0.010
시간 외 거래:
4.14
0.010
+0.24%
전일 마감가:
$4.14
열려 있는:
$4.07
하루 거래량:
449.12K
Relative Volume:
0.52
시가총액:
$396.50M
수익:
-
순이익/손실:
$-238.77M
주가수익비율:
-0.1541
EPS:
-26.808
순현금흐름:
$-216.62M
1주 성능:
+6.44%
1개월 성능:
+36.75%
6개월 성능:
-44.79%
1년 성능:
-67.45%
1일 변동 폭
$4.00
$4.28
1주일 범위
$3.75
$4.28
52주 변동 폭
$2.7601
$13.11
Alumis Inc Stock (ALMS) Company Profile
명칭
Alumis Inc
전화
650-231-6625
주소
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
ALMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
4.13 | 427.20M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 개시 | Wells Fargo | Overweight |
| 2025-06-10 | 재개 | Guggenheim | Buy |
| 2025-01-30 | 개시 | Oppenheimer | Outperform |
| 2024-10-31 | 개시 | Robert W. Baird | Outperform |
| 2024-10-17 | 개시 | H.C. Wainwright | Buy |
| 2024-07-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-23 | 개시 | Guggenheim | Buy |
| 2024-07-23 | 개시 | Leerink Partners | Outperform |
| 2024-07-23 | 개시 | Morgan Stanley | Overweight |
모두보기
Alumis Inc 주식(ALMS)의 최신 뉴스
How does Alumis Inc. compare to its industry peersDaily Trading Outlook With Proven Results - jammulinksnews.com
When is Alumis Inc. stock expected to show significant growthBreakout Stocks Updates With Proven Results - jammulinksnews.com
What institutional investors are buying Alumis Inc. stockTop Growth Planner For Every Investor - jammulinksnews.com
Is Alumis Inc. a growth stock or a value stockStock Strategy Tracker For Every Investor - jammulinksnews.com
What makes Alumis Inc. stock price move sharplyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Alumis (ALMS) Merges with ACELYRIN - Insider Monkey
What is the risk reward ratio of investing in Alumis Inc. stockHarness the power of proven investment plans - jammulinksnews.com
Alumis Inc.: Promising Pipeline and Strategic Advancements Justify Buy Rating - TipRanks
How strong is Alumis Inc. company’s balance sheetTop Growth Entry Points With Low Risk - jammulinksnews.com
What markets is Alumis Inc. expanding into Is ELPW stock a good long term investment optionMaximize returns with smart investment plans - jammulinksnews.com
How does Alumis Inc. generate profit in a changing economyInvest confidently with professional advice - jammulinksnews.com
What is the dividend policy of Alumis Inc. stockUnlock your trading potential today - jammulinksnews.com
What are analysts’ price targets for Alumis Inc. in the next 12 monthsHigh-performance investment picks - jammulinksnews.com
Is Alumis Inc. stock a good hedge against inflationBest Stocks for Capital Safety - metal.it
What analysts say about Alumis Inc. stockAccelerated capital growth - PrintWeekIndia
Alumis Inc. Stock Analysis and ForecastFree Investment Community - PrintWeekIndia
Alumis Inc.: Buy Rating Affirmed Amid Promising ESK-001 Developments and Strong Financial Projections - TipRanks
Alumis initiated with an Overweight at Wells Fargo - TipRanks
What institutions are buying Alumis Inc. stock nowExplosive wealth accumulation - jammulinksnews.com
Is Alumis Inc. a good long term investmentSuperior capital gains - PrintWeekIndia
What drives Alumis Inc. stock priceUnbelievable profit margins - PrintWeekIndia
Alumis completes enrollment in lupus treatment phase 2b trial By Investing.com - Investing.com India
Alumis completes enrollment in lupus treatment phase 2b trial - Investing.com
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus - The Manila Times
Alumis Inc. Completes Patient Enrollment in LUMUS Phase 2b Trial of ESK-001 for Systemic Lupus Erythematosus, Topline Data Expected Q3 2026 - Nasdaq
Major Breakthrough: 408 Patients Enrolled in Advanced Trial for New Oral Lupus Treatment - Stock Titan
Alumis Inc (ALMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alumis Inc 주식 (ALMS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tananbaum James B. | Director |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Labs, LLC | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Labs, LLC | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Capital Management VI | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Capital Management VI | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| AKKARAJU SRINIVAS | Director |
May 05 '25 |
Buy |
4.67 |
160,370 |
749,676 |
3,586,788 |
| AKKARAJU SRINIVAS | Director |
May 02 '25 |
Buy |
4.55 |
159,920 |
727,636 |
3,426,418 |
| Colowick Alan | Director |
Apr 01 '25 |
Buy |
6.97 |
16,104 |
112,309 |
16,104 |
| Colowick Alan | Director |
Apr 02 '25 |
Buy |
7.49 |
2,300 |
17,235 |
18,404 |
| Babler Martin | President, CEO and Chairman |
Apr 01 '25 |
Buy |
6.44 |
15,650 |
100,733 |
106,454 |
0.93%
0.15%
자본화:
|
볼륨(24시간):